期刊文献+

厄贝沙坦/氢氯噻嗪复方片治疗原发性高血压的谷峰比值与平滑指数研究 被引量:13

Study on the T/P ratio and smoothness index of Irbesartan/HCTZ Tablet in the treatment of essential hypertension
下载PDF
导出
摘要 目的:评价厄贝沙坦/氢氯噻嗪复方片(安博诺)对原发性高血压患者降压作用的稳定性。方法:选取50例2级及2级以上的原发性高血压患者,口服安博诺,每日1片,疗程8周,于服药前后进行24h动态血压监测并计算谷峰比值与平滑指数。结果:治疗8周后,24h平均收缩压和舒张压,白昼平均收缩压和舒张压,夜间平均收缩压和舒张压与治疗前比较均有明显下降,差异具有统计学意义(P<0.01),T/P为收缩压75%,舒张压73%,平滑指数为收缩压(1.36±0.45)mmHg,舒张压(1.27±0.31)mmHg(1mmHg=0.133kPa)。结论:厄贝沙坦/氢氯噻嗪复方片对2级及2级以上原发性高血压具有平稳的降压作用。 Objective:To evaluate the smooth control effect of Irbesartan/HCTZ in patients with essential hypertension.Methods:50 patients with moderate and severe essential hypertension were taken orally Irbesartan/HCTZ once a day for 8 weeks.24 hours ambulatory blood pressure monitoring after and before treatment were taken and T/P radio and smoothness index were counted.Results:8 weeks after treatment,compared with before treatment,24 hours systolic blood pressure and 24 hours diastolic blood pressure,day systolic blood pressure and diastolic blood pressure,night systolic blood pressure and diastolic blood pressure had very significantly differences(P0.01),T/P was systolic blood pressure 75%,diastolic blood pressure was 73%,smoothness index was systolic blood pressure(1.36±0.45),diastolic blood pressure was(1.27±0.31).Conclusion:Irbesartan/HCTZ Tablet has smoothly control effect on the patients with moderate and severe essential hypertension.
出处 《中国医药导报》 CAS 2010年第24期54-55,共2页 China Medical Herald
关键词 高血压 厄贝沙坦/氢氯噻嗪复方片 谷峰比值 平滑指数 Hypertension Irbesartan/HCTZ T/P ratio Smoothness index
  • 相关文献

参考文献5

二级参考文献8

  • 1Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2003,42:239-246.
  • 2Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet,2000,29;356:366-372.
  • 3Howe P, Phillips P, Saini R, et al.The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999,21:1373-1396.
  • 4中国高血压防治指南起草委员会.1999中国高血压防治指南[J].高血压杂志,2000,8:94-112.
  • 5European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens,2003,21:1011-1053.
  • 6Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.Lancet. 1998,351:1755-1762.
  • 7张维忠,中华心血管病杂志,1994年,22卷,37页
  • 8蒋雄京,李卫,马林茂,孔灵芝,金水高,刘力生.医院门诊就诊人群高血压相关知识及其对高血压防治的影响[J].中华流行病学杂志,2002,23(4):269-272. 被引量:40

共引文献2733

同被引文献72

引证文献13

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部